EFSA sets a first group ADI in 2017
In 2017 EFSA conducted a full re-evaluation of all six permitted glutamate additives (E620-E625) as a group. For the first time it set a combined group acceptable daily intake of 30 milligrams of glutamic acid equivalent per kilogram of body weight per day, replacing the previous 'not specified' assumption that implied no concern at typical dietary levels. EFSA concluded that the glutamate additives are broken down and handled in the body the same way as naturally occurring glutamate, but that exposure from added glutamates alone could approach or exceed this level in high consumers, particularly children with a diet heavy in processed foods.
EFSA set a group ADI of 30 mg glutamic acid equivalent per kg body weight per day for E620-E625, finding that children who are high consumers of processed foods may exceed this from additive sources alone, not counting natural dietary glutamate.
2017Regulatory reviewEFSA ANS Panel, Re-evaluation of glutamic acid (E620), sodium glutamate (E621), potassium glutamate (E622), calcium diglutamate (E623), ammonium glutamate (E624) and magnesium diglutamate (E625), EFSA Journal
Prior to 2017, the ADI for glutamates was listed as 'not specified', implying no safety concern at levels needed to achieve a flavour effect. The 2017 re-evaluation changed this position based on updated animal toxicology data.
2017Regulatory reviewEFSA ANS Panel, EFSA Journal
The 'Chinese Restaurant Syndrome' debate
From the 1960s onwards, some people reported headaches, flushing and chest tightness after eating MSG-containing meals, a cluster labelled 'Chinese Restaurant Syndrome'. Subsequent double-blind, placebo-controlled trials found that the symptoms could not be reliably reproduced when glutamate was given without people knowing whether they had received it or a placebo. The scientific consensus now is that a specific dose-dependent glutamate sensitivity has not been demonstrated in controlled conditions, though a small number of self-identified sensitive individuals continue to report reactions.
Double-blind crossover trials found that reported MSG sensitivity was not consistently reproduced when participants were unaware of which substance they had consumed, and symptoms did not correlate with dose.
2000RCTGeha et al., Journal of Allergy and Clinical Immunology
A Cochrane-style review concluded that available evidence does not support the existence of a definable MSG sensitivity syndrome, while acknowledging the body of trials is small and some methodological limitations remain.
2006ObservationalFreeman, Journal of the American Academy of Nurse Practitioners
Animal studies at very high doses
Studies in rodents given very large doses of glutamate, far above any realistic food exposure, showed lesions in the hypothalamus and effects on appetite-regulating hormones. Regulators and most researchers consider these findings an artefact of dosing at levels that overwhelm the body's normal glutamate handling mechanisms, not evidence of harm at dietary levels. EFSA examined this literature in its 2017 review and determined that the animal data did not indicate a concern at the ADI it established.
Rodent studies involving oral doses of glutamate at several grams per kilogram body weight produced hypothalamic lesions; EFSA concluded these effects were not relevant to human dietary exposure at the group ADI of 30 mg/kg bw/day.
2017AnimalEFSA ANS Panel, EFSA Journal